ライフサイエンスコーパス: IQR

1 of additional antibiotic treatment was 0.0 (IQR, 0.0-2.0) versus 3.0 (2.0-5.0) (P = .004) in the WOC

2 During median follow-up of 3.0 (IQR 1.2-4.8) years, 613 (41%) patients died.

3 an time between successful contacts was 3.0 (IQR, 3.0-3.7) months.

4 Median DDS was 3.0 (IQR: 2.5-3.5).

5 ined 20.5 letters (IQR, 8.0-28.5) from 55.0 (IQR, 26.0-65.0), and eyes with PDR gained 15.0 letters (

6 ined 15.0 letters (IQR, 6.0-29.5) from 55.0 (IQR, 35.0-61.0).

7 erquartile range [IQR], 5.0-20.0) from 65.0 (IQR, 58.0-70.0) before surgery, eyes with mild or modera

8 ined 10.0 letters (IQR, 5.0-22.0) from 65.0 (IQR, 58.0-76.0), eyes with severe NPDR gained 20.5 lette

9 4.0 [interquartile range {IQR} 7.0] vs 11.0 [IQR 17.0], P < .001) and shorter median career duration

10 1) and shorter median career duration (12.0 [IQR 11.0] vs. 25.0 [IQR 20.0] years, P < .001) than male

11 terquartile range {IQR}, 11.0-26.0] vs 13.0 [IQR, 9.0-19.0]; P < .001).

12 Likewise, the median MoCA score (22.0 [IQR 17.0-26.0] in 150 mg S44819 group, 23.0 [19.0-26.5]

13 n career duration (12.0 [IQR 11.0] vs. 25.0 [IQR 20.0] years, P < .001) than males but similar median

14 .25-1.01), 0.11 (IQR: 0.07-0.13), and 0.028 (IQR: 0.026-0.034) Gy/GBq, respectively.

15 patients in the acetaminophen group and 1.1 (IQR, 0.1-6.6) minutes per hour among patients in the pla

16 TNF-alpha therapy and TB diagnosis was 13.1 (IQR, 7.1-20.3) months.

17 time for initial SARS-CoV-2 in serum was 1 (IQR 1-2) day after admission corresponding to day 10 (IQ

18 ulcerative colitis (median P-SCCAI score 1 [IQR 1-3]).

19 ore, 0 [interquartile range {IQR} 0-1] vs 1 [IQR 0-2] in patients with any positive BDG test; P = .03

20 day after admission corresponding to day 10 (IQR 8-12) after symptom onset.

21 R]: 0.85-1.04), 0.42 (IQR: 0.25-1.01), 0.11 (IQR: 0.07-0.13), and 0.028 (IQR: 0.026-0.034) Gy/GBq, re

22 edian Glasgow Coma Scale (GCS) score was 13 (IQR 9-15), and the leading cause of injury was road-traf

23 in(-1) x mm Hg(-1); p < 0.01; forearm: 5.16 [IQR: 3.86 to 5.43] l x 100 ml of tissue(-1) x min(-1) x

24 etime number of male sexual partners was 17 (IQR: 6, 50) and 246 (19%) were HCV antibody positive.

25 compared to the pre-teleID group (median 19, IQR 11-28), but this decrease was not statistically sign

26 5), median eGFR was 95 ml/min per 1.73 m(2) (IQR, 74-100) using the CKD-EPI formula, 30% had microalb

27 uartile range (IQR), 25-54] versus 53 cm(2) [IQR, 25-65], P=0.09; unipolar: 116 cm(2) [IQR, 61-209] v

28 ) [IQR, 25-65], P=0.09; unipolar: 116 cm(2) [IQR, 61-209] versus 159 cm(2) [IQR, 73-204], P=0.36) for

29 r: 116 cm(2) [IQR, 61-209] versus 159 cm(2) [IQR, 73-204], P=0.36) for the entire study group.

30 Body Mass Index was 24.7 kg/m(2) [IQR, 21.9-28.4 kg/m(2)], eGFR was 105 mL/min/1.73 m(2) [

31 8.4 kg/m(2)], eGFR was 105 mL/min/1.73 m(2) [IQR, 95.7-113.0 mL], 9.7% had metabolic syndrome and 23%

32 0.01], and fraction of inspired oxygen [25% (IQR: 21-31) vs 42% (IQR: 30-80), P < 0.01] differed betw

33 At a median of 28 (IQR, 17-40) months, patients with elevated baseline Zva

34 ls than patients with HCV-negative SS (6.28 [IQR, 0.85] log IU/mL vs 4.08 [2.45] log IU/mL; P < .001)

35 ]) than in the sero-low group (median, 8.3% [IQR, 5.6%-10.23%]) (P = .025).

36 (IQR): -1 to 3 plaques] by 2DVUS; 7.6 mm(3) [IQR: -32.2 to 57.6 mm(3)] by 3DVUS; and 21.6 Agatston un

37 ents compared with other groups (median 30% [IQR 0-40%], 44% [31-70%] and 70% [50-88%], p<0.001).

38 The median age was 31 (IQR 28 to 40).

39 Median follow-up was 5.33 (IQR, 3.05-7.59) years.

40 ian time required to collect the RAI was 33 [IQR 23-53] seconds.

41 and median cost per DALY averted was $3576 (IQR 2474-4918).

42 years; median type 1 diabetes duration, 36 [IQR, 25-48] years; 52% female; 53% insulin pump use; mea

43 QR, 23-47) in AGE hospitalizations, and 36% (IQR, 28-46) AGE mortality.

44 , 46-74) in rotavirus hospitalizations, 36% (IQR, 23-47) in AGE hospitalizations, and 36% (IQR, 28-46

45 dian cost of illness per case of US $196.37 (IQR, US $72.89-496.40).

46 rtile range [IQR], 132-504) cells/uL to 390 (IQR, 216-571) cells/uL from 2006 to 2015.

47 During median follow-up of 5.4 (IQR 5.1-5.9) years, 8828 participants provided a baselin

48 r ex-smokers; median duration of diabetes 4 [IQR: 1-9] years; mean HbA1c 7.4% +/- 1.7%; mean body mas

49 hospital sites (adjusted median rate, 11.4%; IQR, 8.9-14.5).

50 le range [IQR], 4-4) and delamanid-based (4; IQR, 3.5-5) regimens were similar.

51 70 (interquartile range, IQR 55-100) vs 40 (IQR 22-67), P = 0.03].

52 interquartile range [IQR]: 0.85-1.04), 0.42 (IQR: 0.25-1.01), 0.11 (IQR: 0.07-0.13), and 0.028 (IQR:

53 of inspired oxygen [25% (IQR: 21-31) vs 42% (IQR: 30-80), P < 0.01] differed between survivors and no

54 atient antibiotic use could avert 6% to 48% (IQR: 17% to 31%) of exposures across pairwise combinatio

55 Legionella cultures (n = 10, 83.3%) at 49.5 (IQR, 33.7-79) days.

56 n males but similar median m-quotients (0.5 [IQR 0.8] vs 0.5 [IQR 0.8], P = 1.00).

57 ar median m-quotients (0.5 [IQR 0.8] vs 0.5 [IQR 0.8], P = 1.00).

58 2016; P<0.001) but not in HF trials (12.5% [IQR, 0%-20%] in 2001-2004 to 8.9% [IQR, 0%-20%] in 2013-

59 48-77) min, median LP placement times were 5(IQR: 4-6) and 6(IQR: 5-7) min, mild adverse events occur

60 ol/L, and the median triglycerides was 1.50 (IQR = 1.11) mmol/L.

61 median duration of anti-TB treatment was 50 (IQR, 46-66) weeks.

62 than the sero-low volunteers (median, 10.54 [IQR, 8.36-12.12] AU) (P = .006).

63 rs old, there was a median reduction of 59% (IQR, 46-74) in rotavirus hospitalizations, 36% (IQR, 23-

64 an LP placement times were 5(IQR: 4-6) and 6(IQR: 5-7) min, mild adverse events occurred in 4(9.4%) a

65 quacy, on average, by a mean factor of 1.60 (IQR 1.41-1.78).

66 50 (interquartile range [IQR]: 38-71) and 60(IQR: 48-77) min, median LP placement times were 5(IQR: 4

67 96 +/- 125 days, and the median time was 61 (IQR 48-144) days.

68 rotocols achieved a maximum coverage of 65% (IQR 64-65) across GBD regions.

69 72%-78%) in participants with AM versus 65% (IQR, 61%-66%) in HC participants (P < .001).

70 f tissue(-1) x min(-1) x mm Hg(-1) vs. 4.66 [IQR: 3.70 to 6.15] mul x 100 ml of tissue(-1) x min(-1)

71 f tissue(-1) x min(-1) x mm Hg(-1) vs. 5.66 [IQR: 4.69 to 8.38] mul x 100 ml of tissue(-1) x min(-1)

72 ental switching performance was impaired 7% (IQR = 0-19) after indomethacin (P = 0.04), but not signi

73 ) that considers symptoms alone (AUC = 0.71; IQR: 0.63-0.79).

74 low median postoperative mortality of 0.74% (IQR 0.48-0.84).

75 Median early T1 shortening was 75% (IQR, 72%-78%) in participants with AM versus 65% (IQR, 6

76 ex of Multiple Deprivation 2012 decile of 8 [IQR 6-10]), mean systolic BP fell by 6.55 mm Hg (SD 15.1

77 d median glycated hemoglobin level was 8.8% (IQR, 7.4%-10%).

78 ntly higher in the sero-high (median, 21.8% [IQR, 8.15%-29.65%]) than in the sero-low group (median,

79 aining 1500 patients had a median age of 86 (IQR 82-89) years of whom (845 [56%] received non-invasiv

80 [IQR], 45-70) letters, which improved by 9 (IQR, 1-14) letters after the first year of treatment (P

81 s (12.5% [IQR, 0%-20%] in 2001-2004 to 8.9% [IQR, 0%-20%] in 2013-2016; P>0.50).

82 rail Making Test, and the Barthel index (90 [IQR 60-100] in 150 mg S44819 group, 90 [70-100] in 300 m

83 infections of all strategies tested (9,900; [IQR: 8,720-11,400], a 94% reduction), and required fewer

84 ntly higher in the sero-high (median, 17.93 [IQR 12.95-24] arbitrary units [AU]) than the sero-low vo

85 with Crohn's disease (median sCDAI score 93 [IQR 47-156]), and 161 with ulcerative colitis (median P-

86 a median cost of illness per case of $59.99 (IQR, $24.04-$151.23).

87 cipants were close to the null [e.g., for an IQR increase in PNC, RR = 1.17 (95% CI: 1.05, 1.31) vs.

88 led to 13 fewer incident tuberculosis cases (IQR -5 to -18) and four additional severe adverse events

89 million peripheral blood mononuclear cells [IQR 841-2428], n=24; 56-69 years: 797 SFCs [383-1817], n

90 million peripheral blood mononuclear cells, IQR 493-1802; n=43).

91 ribed opioids (range = 1-65 d, median = 4 d, IQR = 3-5 d).

92 he amount of alcohol consumed was 160 g/day [IQR, 120-240 g/day].

93 12.5 days (IQR 9-18) for IgM and 15.0 days (IQR 12-20) for IgG; 54/62 patients (87.1%) sampled at da

94 exposure to standard of care was 85.0 days (IQR 80.0-90.0) and to dabigatran was 84.5 days (78.0-89.

95 n days (IQR:7, 12) in pregnancy and 17 days (IQR:14, 21) postpartum, with steady-state achieved by fi

96 charge from hospital for a median of 2 days (IQR 1-4).

97 Median follow-up was 253 days (IQR 127-448).

98 Median follow-up was 30 days (IQR 27-83).

99 Median follow-up was 379 days (IQR 294-392) for deferiprone and 381 days (350-392) for

100 onversion occurred at a median of 12.5 days (IQR 9-18) for IgM and 15.0 days (IQR 12-20) for IgG; 54/

101 06]), with a median hospital stay of 5 days (IQR, 3-7).

102 nge [IQR]: 6-11) and waiting time 78.5 days (IQR: 29.5-237.5).

103 on of maternal therapy at birth was 55 days (IQR 33-77).

104 uration of index hospitalization was 6 days (IQR, 3-12 days) and 26% required intensive care.

105 oup had a median of 17 ventilator-free days (IQR, 0-27 days) (mean ratio, 1.04; 95% CI, 0.95-infinity

106 oup had a median of 18 ventilator-free days (IQR, 0-27 days) and 493 patients in the higher PEEP grou

107 TFV-DP median half-life was ten days (IQR:7, 12) in pregnancy and 17 days (IQR:14, 21) postpar

108 a who received ambulatory treatment (0 days [IQR 0-3]) than in the 113 with available data who receiv

109 quartile range {IQR} 7.5-11.0] vs 11.0 days [IQR 7.5-18.0], respectively; log-rank test, P = .005).

110 ts over 9 months (median follow-up 226 days [IQR 198-357]).

111 4), and a shorter in-hospital stay (34 days [IQR 18-55] vs 51 days [IQR 35-91] in positive group; P =

112 ble data who received standard care (4 days [IQR 0-8]; p<0.0001; median difference 2 days [95% CI 1-3

113 spital stay (34 days [IQR 18-55] vs 51 days [IQR 35-91] in positive group; P = .003).

114 median time from cellular therapy, 782 days; IQR, 354-1611 days).

115 volume of high-density lung volume (12.26 dl IQR 4.65 dl vs. 7.51 dl vs. IQR 5.39 dl, p = 0.039).

116 rocumab reduced lipoprotein(a) by 5.0 mg/dl (IQR: 0 to 13.5 mg/dl), corrected LDL-C by 51.1 mg/dl (IQ

117 13.5 mg/dl), corrected LDL-C by 51.1 mg/dl (IQR: 33.7 to 67.2 mg/dl), and reduced the risk of MACE (

118 Medians of 20 errors (IQR 14-36) and 8 events (IQR 4-12) were identified per c

119 dians of 20 errors (IQR 14-36) and 8 events (IQR 4-12) were identified per case.

120 the cadmium:creatinine ratio was 0.96 mug/g (IQR: 0.61-1.51).

121 QR): 26.3-28.4], median birth weight 1088 g [IQR: 730-1178].

122 .8 to 4.2 h), n = 583; and standard, 59.9 h (IQR: 38.9 to 86.7 h); n = 440 after the diagnosis of NST

123 Median time to surgery was 11 hours (IQR 4-40).

124 rtile range [IQR], 19-70 hours) vs 26 hours (IQR, 12-51 hours) (difference, 15 hours [95% CI, 11 to 2

125 protein [138 mg/L (IQR: 83-179) vs 73 mg/L (IQR: 12-98), P < 0.01), lactate [1.1 mmol/L (IQR: 1.0-1.

126 Median C-reactive protein [138 mg/L (IQR: 83-179) vs 73 mg/L (IQR: 12-98), P < 0.01), lactate

127 IQR: 12-98), P < 0.01), lactate [1.1 mmol/L (IQR: 1.0-1.6) vs 4.6 mmol/L (IQR: 2.8-8.0), P < 0.01], a

128 te [1.1 mmol/L (IQR: 1.0-1.6) vs 4.6 mmol/L (IQR: 2.8-8.0), P < 0.01], and fraction of inspired oxyge

129 g/L; IQR: 0.773 g/L compared with 8.04 g/L; IQR: 0.449 g/L).

130 igosaccharides than nonsecretors (11.45 g/L; IQR: 0.773 g/L compared with 8.04 g/L; IQR: 0.449 g/L).

131 ith mild or moderate DR gained 10.0 letters (IQR, 5.0-22.0) from 65.0 (IQR, 58.0-76.0), eyes with sev

132 5.0), and eyes with PDR gained 15.0 letters (IQR, 6.0-29.5) from 55.0 (IQR, 35.0-61.0).

133 , eyes with severe NPDR gained 20.5 letters (IQR, 8.0-28.5) from 55.0 (IQR, 26.0-65.0), and eyes with

134 Median (IQR) concentration of plasma TMAO was 3.05 mumol/L (2.10

135 Median (IQR) final logarithm of the minimum angle of resolution

136 Median (IQR) incidence of symptomatic antibiotic-treated UTIs wa

137 Median (IQR) psychological stress scores were significantly incr

138 d longer length of stay in hospital [median (IQR):15 (5-34) days vs. 6 (3-11) days; p < 0.001).

139 ved significantly from start of OIT (median (IQR); 4.8, 3.8-5.7) to end of up-dosing (3.9, 3-5.2) (P

140 Of the 70 patients included, the median (IQR) age was 25(22-32) years and 56% were females.

141 The median (IQR) titer difference was 0 (0-1) from baseline to follo

142 lant GNB vs nontransplant GNB: IL-2 (median [IQR]: 7.1 pg/ml [7.1, 7.1] vs 32.6 pg/ml [7.1, 88.0]; p

143 After a median [IQR] follow-up time of 21 [20-22] y, 2131 participants h

144 droxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73

145 arly-life risk factor for FE (weeks, median [IQR]: FE, 0 [0-1.75] vs. IE, 6 [0-20], P < .001).

146 The median(IQR) duration of exposure to BDQ and DLM was 77(43-96) w

147 assemblies containing 40 molecules (median) (IQR: 23, 87) of 5-LO, and 53 molecules (62, 156) of FLAP

148 The median total procedure time was 125 min (IQR: 108 to 166 min) (including a median of 28 min [IQR:

149 r voltage mapping), with a median of 16 min (IQR: 12 to 23 min) fluoroscopy.

150 8 to 166 min) (including a median of 28 min [IQR: 25 to 33 min] for voltage mapping), with a median o

151 nterquartile range [IQR], 17-41] vs. 60 min [IQR, 45-60], P = 0.002).

152 f 24 patients; median ablation time: 10 min; IQR: 6 to 13 min) were 100% acutely successful with the

153 chieved in 13 of 13 patients (median: 9 min; IQR: 6 to 12 min).

154 of hypotension per patient was 8.0 minutes (IQR, 1.33-26.00 minutes) in the intervention group vs 32

155 ) in the intervention group vs 32.7 minutes (IQR, 11.5-59.7 minutes) in the control group, for a medi

156 ansfused was 40 mL (IQR, 16-73 mL) vs 19 mL (IQR, 0-46 mL); and weekly mean hematocrit was 3 percenta

157 (60.5%); median volume transfused was 40 mL (IQR, 16-73 mL) vs 19 mL (IQR, 0-46 mL); and weekly mean

158 V volumes (percentage increase, 28%; 206 mL [IQR, 170-253] versus 263 mL [IQR, 204-294], P<0.001) for

159 e, 28%; 206 mL [IQR, 170-253] versus 263 mL [IQR, 204-294], P<0.001) for the entire study population.

160 inter-site systolic variability was 10 mmHg (IQR 2 to 10 mmHg).

161 averted per 10 000 children receiving MNPs (IQR 20.6-40.4), and median cost per DALY averted was $35

162 n follow-up among survivors was 13.0 months (IQR 11.7-23.5).

163 2019), the median follow-up was 22.0 months (IQR 12.0-26.7) for the EZH2(mut) cohort and 35.9 months

164 Median follow-up was 19.0 months (IQR 15.0-23.4).

165 edian duration of follow-up was 24.0 months (IQR 21.4-28.1) and 35 of 41 patients who had tumour rese

166 8), after a median follow-up of 11.0 months (IQR 6.8-23.0), all patients had discontinued enasidenib,

167 Median follow-up was 28.1 months (IQR 22.0-33.6).

168 At a median follow-up of 40.1 months (IQR 37.4-43.1), a significant benefit in overall surviva

169 Median follow-up was 17.1 months (IQR 6.5-25.3).

170 Median follow-up was 10 months (IQR 6-15).

171 The median follow-up was 61.2 months (IQR 53.8-70.0) for the 57 patients evaluable for respons

172 Median follow-up was 13.2 months (IQR 7.3-20.4) as of data cutoff on Nov 30, 2018.

173 p at the time of data cutoff was 2.3 months (IQR 1.6-3.5).

174 .0001) at a median follow-up of 30.3 months (IQR 18.0-47.5).

175 Median follow-up was 38.3 months (IQR 20.7-46.1, range 0-138.0; 95% CI 37.8-38.7).

176 2019), at a median follow-up of 6.3 months (IQR 3.2-8.2) in the ripretinib group and 1.6 months (1.1

177 duration of study follow-up was 9.3 months (IQR 5.1-15.7) at the time of data cutoff.

178 ian follow-up after diagnosis was 34 months (IQR: 17 to 54 months).

179 2019, at a median follow-up of 28.4 months (IQR 17.7-36.8), median recurrence-free survival was not

180 l analysis, median follow-up was 7.4 months (IQR 3.5-13.9).

181 Median follow-up was 91.4 months (IQR 75.1-105.6).

182 data cutoff (July 10, 2018) was 12.4 months (IQR 8.3-21.7) in the experimental group and 11.3 months

183 After a median follow-up of 42 months (IQR 22-67), 33 (28%) of the 116 patients had relapses, i

184 At a median follow-up of 44 months (IQR 20-61), overall survival at 5 years was 54% (95% CI

185 The median follow-up was 8.5 months (IQR 3.1-12.2).

186 At a median follow-up of 7.5 months (IQR 6.5-9.3), overall response and C(trough) met the pre

187 At a median follow-up of 71.5 months (IQR 71.3 to 71.7), the primary endpoint event occurred i

188 3, 2020), median follow-up was 20.6 months (IQR 8.7-24.9) in the atezolizumab plus chemotherapy grou

189 The median follow-up was 13.7 months (IQR 12.7-14.4).

190 median duration of follow-up of 19.7 months (IQR 15.9-25.9).

191 data cutoff (April 5, 2019) was 35.7 months (IQR 24.9-43.6) in the veliparib group and 35.5 months (2

192 across all treatment groups was 14.7 months (IQR 7.8-24.1).

193 The median follow-up was 17.8 months (IQR 11.6-21.3).

194 At a median follow-up of 13.8 months (IQR 7.8-19.0), median duration of response was not reach

195 Median time to response was 3.9 months (IQR 1.9-7.4).

196 At a median follow-up of 18.9 months (IQR 10.4-23.8), progression-free survival as assessed by

197 Median follow-up was 19.9 months (IQR 10.7-23.1).

198 b 6, 2018, median follow-up was 62.9 months (IQR 58.1-74.1).

199 the median follow-up period was 12.9 months (IQR 6.2-22.9).

200 Median follow-up durations were 13.2 months [IQR 6.2-19.8] for the selinexor, bortezomib, and dexamet

201 (95% CI 12-18; actual follow-up 6.5 months; IQR 3.4-12.4).

202 men had a median CD4 count of 537 cells/mul (IQR: 483 to 741) at enrollment and HIV plasma viral load

203 :691, 1166) in pregnancy vs 1406 fmol/punch (IQR:1053, 1859) postpartum (p=0.006).

204 dian steady-state TFV-DP was 965 fmol/punch (IQR:691, 1166) in pregnancy vs 1406 fmol/punch (IQR:1053

205 nce between 75th and 25th percentile (Q3-Q1) IQRs of macronutrient intake distributions.

206 of 138 times per case [interquartile range (IQR) 96-190].

207 The odds ratio (OR) per interquartile range (IQR) increase [9,200 particles per cubic centimeter (cc)

208 sted associations of an interquartile range (IQR) increase in log(2)-transformed PFAS for each time p

209 ility was 6mmHg with an interquartile range (IQR) of 3 to 9 mmHg.

210 d for a median of 24.2 (interquartile range (IQR), 14.2-34.5) months, corresponding to 8,529 successf

211 ved (bipolar: 38 cm(2) [interquartile range (IQR), 25-54] versus 53 cm(2) [IQR, 25-65], P=0.09; unipo

212 admission was 47 years [interquartile range (IQR), 40-53 years], age of onset of alcohol consumption

213 sion (median: 1 plaque [interquartile range (IQR): -1 to 3 plaques] by 2DVUS; 7.6 mm(3) [IQR: -32.2 t

214 he curve (AUC) of 0.80 (interquartile range (IQR): 0.73-0.86) for discriminating between symptomatic

215 was lower (calf: 3.30 [interquartile range (IQR): 2.33 to 3.88] l x 100 ml of tissue(-1) x min(-1) x

216 ational age 26.9 weeks [interquartile range (IQR): 26.3-28.4], median birth weight 1088 g [IQR: 730-1

217 e ratio was 7.54 mug/g [interquartile range (IQR): 4.90-11.93] and the cadmium:creatinine ratio was 0

218 w-up time of 5.9 years (interquartile range [IQR] 1.1-14.2).

219 a viral load 498 IU/mL, interquartile range [IQR] 259-2390).

220 l emphysema was 8 days (interquartile range [IQR] 5-15 days).

221 11 doses of eculizumab (interquartile range [IQR] 7-20).

222 eleID group (median 15, interquartile range [IQR] 9-25), compared to the pre-teleID group (median 19,

223 and MRI was 35 minutes (interquartile range [IQR] = 24-50).

224 ian age was 17.0 years (interquartile range [IQR] = 9.0-29.0 years; range = 0-80 years), with 1,584 (

225 24-2 VF MD was -6.8 dB (interquartile range [IQR], -4.9 to -12.3 dB).

226 F treatment (median, 4; interquartile range [IQR], 0-12).

227 less than 90%, was 0.7 (interquartile range [IQR], 0.1-5.1) minutes per hour among patients in the ac

228 ral load of 0.54 cp/ml (interquartile range [IQR], 0.22 to 1.46 cp/ml) and a 14% (95% confidence inte

229 dian age was 2.8 years (interquartile range [IQR], 1.3 to 5.3); 8.5% (30/353) were HIV infected, and

230 sis increased from 326 (interquartile range [IQR], 132-504) cells/uL to 390 (IQR, 216-571) cells/uL f

231 normal sleep: (30 min [interquartile range [IQR], 17-41] vs. 60 min [IQR, 45-60], P = 0.002).

232 d follow-up of 30 days (interquartile range [IQR], 17-46 days).

233 life span was 47 hours (interquartile range [IQR], 19-70 hours) vs 26 hours (IQR, 12-51 hours) (diffe

234 patients was 53 years (interquartile range [IQR], 33-69 years) and 100 (48.3%) were female.

235 n bedaquiline-based (4; interquartile range [IQR], 4-4) and delamanid-based (4; IQR, 3.5-5) regimens

236 ian baseline VA was 60 (interquartile range [IQR], 45-70) letters, which improved by 9 (IQR, 1-14) le

237 Study (ETDRS) letters (interquartile range [IQR], 5.0-20.0) from 65.0 (IQR, 58.0-70.0) before surger

238 n age was 60 years old (interquartile range [IQR], 54, 66), and 23% were African American.

239 : median age, 59 years; interquartile range [IQR], 54-64 years).

240 5 children was 26 days (interquartile range [IQR], 7-106 days).

241 bone marrow were 0.88 (interquartile range [IQR]: 0.85-1.04), 0.42 (IQR: 0.25-1.01), 0.11 (IQR: 0.07

242 ents-very early, 2.5 h (interquartile range [IQR]: 1.8 to 4.2 h), n = 583; and standard, 59.9 h (IQR:

243 ablation time: 22 min; interquartile range [IQR]: 15 to 29 min) and LAPW ablation (24 of 24 patients

244 in Network 6 was 33.7% (interquartile range [IQR]: 25.3%-43.1%).

245 rocedure times were 50 (interquartile range [IQR]: 38-71) and 60(IQR: 48-77) min, median LP placement

246 ase score at LT was 7 ((interquartile range [IQR]: 6-11) and waiting time 78.5 days (IQR: 29.5-237.5)

247 PCOS cases (median and interquartile range [IQR]: age = 28 [25-32], body mass index [BMI] = 35.4 [28

248 (median Pitt score, 0 [interquartile range {IQR} 0-1] vs 1 [IQR 0-2] in patients with any positive B

249 median h-indices (4.0 [interquartile range {IQR} 7.0] vs 11.0 [IQR 17.0], P < .001) and shorter medi

250 ero-high group (9 days [interquartile range {IQR} 7.5-11.0] vs 11.0 days [IQR 7.5-18.0], respectively

251 (median age, 1.7 years [interquartile range {IQR}, 0.1-6.9]) compared with immune-mediated encephalit

252 controls (median, 17.0 [interquartile range {IQR}, 11.0-26.0] vs 13.0 [IQR, 9.0-19.0]; P < .001).

253 [median age, 29 years; interquartile range {IQR}, 24-36 years; 84 men]) were used to build CT scores

254 n (median age, 9 years [interquartile range {IQR}, 5.7-14]; 20 girls [34%]) were identified who met t

255 trial (median age, 66 [interquartile range {IQR}, 56-74] years; 246 [36%] women).

256 ipants (median age, 68 [interquartile range {IQR}, 65-71] years; median type 1 diabetes duration, 36

257 ublications [median 70 (interquartile range, IQR 55-100) vs 40 (IQR 22-67), P = 0.03].

258 oup), time needed to complete parts A (50 s [IQR 42-68] in 150 mg S44819 group, 49 s [36-63] in 300 m

259 est additional severe adverse events (seven [IQR 5 to 8] per 1000 adults aged 18-34 years and 35-64 y

260 01) influenced by age and race; however, the IQR of protein intake was not associated with demographi

261 The IQRs of carbohydrate and fat intake distributions were s

262 r of previous anticancer regimens was three (IQR 2-4).

263 .6 mm(3)] by 3DVUS; and 21.6 Agatston units [IQR: 4.8 to 62.6 Agatston units] by CACS).

264 terquartile range of normalized ventilation (IQR(N); as a measure of ventilation heterogeneity) was c

265 volume (12.26 dl IQR 4.65 dl vs. 7.51 dl vs. IQR 5.39 dl, p = 0.039).

266 viremia, confirmatory testing took 29 weeks (IQR: 16-54).

267 ion decreased below the LLOQ was 43.7 weeks (IQR 31.1-66.6; range 20.4-152.5) for male participants a

268 oup than the azathioprine group (78.9 weeks [IQR 58.3-90.6] vs 56.7 [32.9-81.7] weeks; p=0.0026).

269 milar between trials at 64 or 65 years (with IQRs ranging from 59 to 68 years) across the three trial

270 line, median intake of SSBs was 472.1 mL/wk (IQR: 198.8-1416.4 mL/wk), and 233 participants had hyper

271 ow-up time for the HPV group was 11.1 years (IQR 9.1-11.7), 4.6 years (4.3-5.3) for the original cont

272 n age of the enrolled patients was 13 years (IQR 8-15).

273 90 patients, with a median age of 14 years (IQR 10-17), were enrolled.

274 Median age of participants was 14 years (IQR 10-29) and 153 (52%) were female.

275 At enrolment, the median age was 15 years (IQR 14-17), 52% of adolescents were female, 81% were orp

276 IOP control with median time of 3.17 years (IQR, 0.92-6.56) from first surgery.

277 polycythaemia vera diagnosis was 8.2 years (IQR 3.9-12.3) in the ruxolitinib group and 9.3 years (4.

278 Participant median age was 20 years (IQR:19,22).

279 maternal age of included women was 26 years (IQR 22-30).

280 ng 91 patients, the median age was 26 years (IQR, 11-47).

281 Median age was 40 years (IQR 35-48), CD4 cell count was 683 cells per muL (447-93

282 the end of the present study, was 5.5 years (IQR 4.26-7.14).

283 At a median follow-up of 6.5 years (IQR 4.9-7.9), 5-year event-free survival and overall sur

284 who were assessed for a median of 9.5 years (IQR 8.5-10.9).

285 Median age was 58 years (IQR, 52-65), median eGFR was 95 ml/min per 1.73 m(2) (IQ

286 With a median follow-up of 2.6 years (IQR 1.8-2.9) in the ipilimumab group, 2.4 years (2.2-2.6

287 The median age of participants was 62 years (IQR 56-69) in 2015, and 5766 (48.8%) participants were m

288 Median age was 64 years (IQR 57-70, range 36-85).

289 were balanced with a median age of 65 years (IQR 60-68).

290 S and followed up for a median of 9.7 years (IQR 5.8-13.6).

291 ge of the 452 matched patients was 75 years (IQR, 67-82 years) and 51.8% of patients were men.

292 atients and a median follow-up of 0.8 years (IQR 0.3-1.6) in the pazopanib group and 1 year (0.3-1.6)

293 ollow-up for the CCSS cohort was 23.9 years (IQR 20.4-27.9), and for SJLIFE it was 23.9 years (19.0-3

294 With a median follow-up of 4.9 years (IQR 3.9-8.4), median overall survival for patients with

295 f onset of alcohol consumption was 16 years [IQR, 16-18 years] and the amount of alcohol consumed was

296 ediated encephalitis (median age, 7.6 years [IQR, 4.6-12.4]).

297 were female and with median age of 64 years [IQR 56-70, range 22-89] and median Scottish Index of Mul

298 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive

299 Of 614 patients (median age 69 years, (IQR 25) and 62% male), 381 (62%) had been discharged ali

300 center 2, 53 patients [median age, 27 years; IQR, 22-35 years; 34 men]) using the Spearman rank coeff

301 th 19 HC participants (median age, 39 years; IQR, 28-46 years; seven women).